Case number# PHEH2015US005847, is a combined initial and follow up report received from a physician and 
nurse via a patient oriented program Gilenya Go Program POP00002581 on 23 Mar 2015. 
This report refers to a 34 year old female patient. Medical history was not reported. Concomitant medication 
included ibuprofen (manufacturer unknown). 
The patient received Gilenya (fingolimod) capsule for the treatment of multiple sclerosis (MS) from 29 Aug 2013 at 
a dose of 0.5 mg, QD (oral). 
On an unknown date, the patient was diagnosed with MS and the pattern of MS was relapsing remitting multiple 
sclerosis (RRMS).  The patient JC virus antibody was positive (JC virus test positive) - date unknown. 
The patient had  vitamin D deficiency with a value of 17.6 L (normal range: 30 to 100 ng/ml). The patient was 
treated with Vitamin D (ergocalciferol) 50000U capsule. On replacement, the vitamin D level was 25.1 after 8 weeks
of 50 K unit dose.   On 28 Oct 2014, white blood cell (WBC) count was 3.6 (white blood cell count decreased) 
(normal range and units were not reported). The patient reported with low absolute lymphocytes with value of 0.2 
(lymphocyte count decreased) (normal range and units were not reported), while on Gilenya.
As per the notes of physician dated 11 Nov 2014, the patient weight was 260 (unit unspecified). The physical 
examination findings included morbidly obese (obesity),   The patient required MRI due to excessive fatigue.  MRI 
21 Nov 2014 showed deep white matter lesions, no acute demyelination; C7 lesions non-enhancing.
On 20 Jan 2015, the patient symptoms had unchanged since visit of 27 Oct 2014. Initial symptoms were left leg 
numbness (hypoaesthesia) and weakness (muscular weakness), then left hand tingling (paresthesia). The duration 
of the symptoms were mild and were persistent. The treatment drug Gilenya was administered and so far had been
effective. Magnetic resonance imaging (MRI) spine and brain impression findings were reported consistent with 
prior demyelination without any abnormal enhancement or other evidence to suggest this was an acute 
demyelinating plaque. 
The patient also had malaise and fatigue, which related to working in the night shift and taking care of kids. The 
patient comprehensive metabolic panel (CMP) was performed in Jan 2015 and the results were in the normal 
range. Action taken with Gilenya was ongoing.
Outcome of the events muscular weakness, paresthesia and hypoaesthesia was reported as complete recovery 
and for other events was reported as unknown. Seriousness and causality of the events was not reported. 
Seriousness of the event RRMS was upgraded based on the NVS IME list. Seriousness of the event JC virus test 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 260 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
positive was upgraded based on the information available in source documents.